CCXI $7.00 +.12 Float 18.6m w/cash $1.60 per share and no debt...on favorable clinical trial results:

ChemoCentryx Announces Immuno-Oncology Data Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
ChemoCentryx, Inc.
46 minutes ago
GlobeNewswire

-- In pancreatic cancer patient trial, excellent receptor blockade achieved with chemokine receptor CCR2 inhibitor CCX872, bodes well for ongoing multi-dose part of clinical trial; Patient enrollment reaches 20 percent of target --

-- In triple negative breast cancer model, small molecule inhibitor of chemokine receptor CCR1 potentiates anti-tumor effect in combination with PD-L1 checkpoint inhibitor --

MOUNTAIN VIEW, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that two abstracts from the Company's immuno-oncology programs have been selected for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 5-9, 2015 in Boston, Massachusetts. The abstracts highlight clinical stage results in a pancreatic cancer trial with CCX872, the Company's second inhibitor of the chemokine receptor known as CCR2, and, separately, preclinical results in a model of triple negative breast cancer using combination therapy employing an antibody against the checkpoint inhibitor PD-L1 in conjunction with CCX9588, an inhibitor of the chemokine receptor known as CCR1.

"Tumors have devised ways to suppress anti-tumor immune responses in part by importing immune suppressor cells into the tumor microenvironment. One goal of our chemoattractant based immuno-oncology program is to develop treatments that specifically reduce the content of immune suppressive elements in the tumor mass, thus enabling the body's effector immune response to predominate," said Thomas J. Schall, Ph.D., President and Chief Executive Officer. "Towards this end, in our pancreatic cancer trial we are encouraged by observations to date of excellent coverage of the receptor CCR2, which guides suppressor cells to the tumor, by our drug CCX872, and we except to see greater than 90 percent receptor coverage continuously in the ongoing multi-dose portion of the study. Patient recruitment in the trial is ramping up, having reached 20 percent of the target enrollment, and we look forward to efficacy data from this trial in 2016. Also, our preclinical model work using a combination of checkpoint inhibitor antibody therapy in combination with an orally administered chemokine receptor inhibitor may pave the way for new treatment options in such important areas as triple negative breast cancer."

Part A Results of Pancreatic Cancer Clinical Trial for CCX872

Pharmacokinetic and pharmacodynamic profile of the novel, oral and selective CCR2 inhibitor CCX872-B in a Phase Ib pancreatic cancer trial, Hezel et al, (Abstract #B24, poster presentation November 7 from 12:30-3:30 p.m. ET, Session B, Hall C-D)

In the ongoing clinical trial in patients with pancreatic cancer with the Company's CCR2 inhibitor, CCX872, all patients are receiving FOLFIRINOX and CCX872. The two-part trial includes Part A, in which patients receive a single dose of CCX872, and Part B, in which patients receive once or twice daily doses of CCX872 initially for 12 weeks with the ability to continue treatment unless disease progression or unacceptable intolerability occurs. In the trial, the Company plans to evaluate CCX872 in up to 54 patients. The primary efficacy measurement is progression-free survival when patients have completed at least 24 weeks of treatment.

From the abstract, after a single dose of CCX872, across four patients in Part A, the pharmacokinetic profile was favorable and pharmacodynamic assays demonstrated excellent receptor coverage after 12 hours. With 4 to 5-fold accumulation of plasma concentrations with twice daily dosing in Part B, the authors expect to see greater than 90 percent coverage of the receptor throughout the day.


8:33 am ChemoCentryx to report data regarding CCX872 at the AACR-NCI-EORTC International Conference; results show that the CCX872 pharmacokinetic profile was favorable Briefing.com 1 hr 9 mins ago
CHEMOCENTRYX, INC. Financials EDGAR Online Financials 2 mths ago
More
Preclinical Data of Combination Therapy of Chemokine Receptor and Checkpoint Inhibitors

Combination therapy of chemokine receptor inhibition plus PD-L1 blockade potentiates anti-tumor effects in a murine model of breast cancer, Jung et al, (Abstract #A90, poster presentation November 6 from 12:15-3:15 p.m. ET, Session A, Hall C-D)

The Company's immuno-oncology program is pursuing a better understanding of the body's immune response to tumors and is therefore conducting studies with various chemokine receptor inhibitors in combination with checkpoint inhibitors that may result in beneficial anti-tumor effects. Results from a study of one of the Company's inhibitors of the chemokine receptor known as CCR1, CCX9588, demonstrated the ability to act synergistically with a PD-L1 inhibitor to reduce tumor burden in a preclinical model of triple negative breast cancer.

From the abstract, CCX9588, when delivered in combination with an anti-PDL1 antibody, resulted in significantly reduced primary tumor growth and lung metastasis, as compared to either agent alone. In addition, an analysis of tumor-infiltrating cells revealed that the addition of CCX9588 to the anti-PD-L1 antibody significantly reduced the number of myeloid derived suppressor cells (MDSCs) in primary tumors, potentially contributing to the overall reduction of tumor burden. These preclinical results were also accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held from November 4-8, in National Harbor, MD.

"One of the most exciting advances in oncology in decades is the recent observation that modifiers of the activity of the body's own immune system can profoundly enhance the response to chemotherapy," said Israel F. Charo, M.D., Ph.D., Senior Vice President, Research, ChemoCentryx. "We believe that chemokine receptor inhibitors such as CCX9588, combined with immunotherapy or traditional chemotherapy, may result in greater efficacy and fewer systemic side effects."

About the ChemoCentryx Immuno-Oncology Program

CCR1- and CCR2-bearing cells, such as myeloid derived suppressor cells (MDSCs), are thought to possess an immunosuppressive behavior. MDSCs effectively help tumors hide from the body's natural cytotoxic immune response to tumor cells. Inhibiting CCR1 and CCR2, may lead to the liberation of the cytotoxic immune response against tumor cells, reduced tumor burden and potentially lead to improved patient survival.

The Company currently has an ongoing clinical trial of CCX872, an inhibitor of the chemokine receptor known as CCR2, in patients with non-resectable pancreatic cancer. In addition, the Company is conducting preclinical research with various chemokine receptor inhibitors in combination with checkpoint inhibitors, such as those inhibiting the PD-L1 pathway, which may result in a greater anti-tumor effect than with checkpoint inhibition alone. CCX9588 is a small molecule inhibitor of CCR1 and is currently in preclinical development for certain oncology indications targeting both solid and liquid tumors.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX140, a CCR2 inhibitor, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvements in kidney function in patients with diabetic nephropathy. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing both reduction and elimination of high-dose corticosteroids, part of standard of care for AAV patients, without compromising efficacy or safety during a 12-week treatment period. CCX168 is also in Phase II pilot studies for the treatment of atypical Hemolytic Uremic Syndrome (aHUS) and Immunoglobulin A nephropathy, or IgA nephropathy (IgAN). CCX872, a second CCR2 inhibitor, successfully completed Phase I development and is in development for the treatment of non-resectable pancreatic cancer. Vercirnon (also known as Traficet-EN or CCX282) is a specific CCR9 inhibitor for the treatment of inflammatory bowel disease. Other clinical programs include CCX507, a next generation CCR9 inhibitor, which has successfully completed Phase I development and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.

Forward-Looking Statements

ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding the achievement of anticipated milestones in 2015 and 2016 and whether the Company's drug candidates CCX872 and CCX9588 will be shown to be effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC March 13, 2015 and its other reports which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Source: ChemoCentryx, Inc.

CCXI-G

Contact:
Susan M. Kanaya
Senior Vice President, Finance and
Chief Financial Officer or
Markus J. Cappel, Ph.D.
Chief Business Officer
650.210.2900
investor@chemocentryx.com
Media:
Denise Powell
510.703.9491
denise@redhousecomms.com
Investors:
Kimberly Minarovich
Burns McClellan
212.213.0006
kminarovich@burnsmc.com

GL all....tuna

CCXI $7.00 +.12 Float 18.6m w/cash $1.60 per share and no debt...on favorable clinical trial results:

ChemoCentryx Announces Immuno-Oncology Data Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
ChemoCentryx, Inc.
46 minutes ago
GlobeNewswire


-- In pancreatic cancer patient trial, excellent receptor blockade achieved with chemokine receptor CCR2 inhibitor CCX872, bodes well for ongoing multi-dose part of clinical trial; Patient enrollment reaches 20 percent of target --

-- In triple negative breast cancer model, small molecule inhibitor of chemokine receptor CCR1 potentiates anti-tumor effect in combination with PD-L1 checkpoint inhibitor --

MOUNTAIN VIEW, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today announced that two abstracts from the Company's immuno-oncology programs have been selected for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 5-9, 2015 in Boston, Massachusetts. The abstracts highlight clinical stage results in a pancreatic cancer trial with CCX872, the Company's second inhibitor of the chemokine receptor known as CCR2, and, separately, preclinical results in a model of triple negative breast cancer using combination therapy employing an antibody against the checkpoint inhibitor PD-L1 in conjunction with CCX9588, an inhibitor of the chemokine receptor known as CCR1.

"Tumors have devised ways to suppress anti-tumor immune responses in part by importing immune suppressor cells into the tumor microenvironment. One goal of our chemoattractant based immuno-oncology program is to develop treatments that specifically reduce the content of immune suppressive elements in the tumor mass, thus enabling the body's effector immune response to predominate," said Thomas J. Schall, Ph.D., President and Chief Executive Officer. "Towards this end, in our pancreatic cancer trial we are encouraged by observations to date of excellent coverage of the receptor CCR2, which guides suppressor cells to the tumor, by our drug CCX872, and we except to see greater than 90 percent receptor coverage continuously in the ongoing multi-dose portion of the study. Patient recruitment in the trial is ramping up, having reached 20 percent of the target enrollment, and we look forward to efficacy data from this trial in 2016. Also, our preclinical model work using a combination of checkpoint inhibitor antibody therapy in combination with an orally administered chemokine receptor inhibitor may pave the way for new treatment options in such important areas as triple negative breast cancer."

Part A Results of Pancreatic Cancer Clinical Trial for CCX872

Pharmacokinetic and pharmacodynamic profile of the novel, oral and selective CCR2 inhibitor CCX872-B in a Phase Ib pancreatic cancer trial, Hezel et al, (Abstract #B24, poster presentation November 7 from 12:30-3:30 p.m. ET, Session B, Hall C-D)

In the ongoing clinical trial in patients with pancreatic cancer with the Company's CCR2 inhibitor, CCX872, all patients are receiving FOLFIRINOX and CCX872. The two-part trial includes Part A, in which patients receive a single dose of CCX872, and Part B, in which patients receive once or twice daily doses of CCX872 initially for 12 weeks with the ability to continue treatment unless disease progression or unacceptable intolerability occurs. In the trial, the Company plans to evaluate CCX872 in up to 54 patients. The primary efficacy measurement is progression-free survival when patients have completed at least 24 weeks of treatment.

From the abstract, after a single dose of CCX872, across four patients in Part A, the pharmacokinetic profile was favorable and pharmacodynamic assays demonstrated excellent receptor coverage after 12 hours. With 4 to 5-fold accumulation of plasma concentrations with twice daily dosing in Part B, the authors expect to see greater than 90 percent coverage of the receptor throughout the day.


8:33 am ChemoCentryx to report data regarding CCX872 at the AACR-NCI-EORTC International Conference; results show that the CCX872 pharmacokinetic profile was favorable Briefing.com 1 hr 9 mins ago
CHEMOCENTRYX, INC. Financials EDGAR Online Financials 2 mths ago
More
Preclinical Data of Combination Therapy of Chemokine Receptor and Checkpoint Inhibitors

Combination therapy of chemokine receptor inhibition plus PD-L1 blockade potentiates anti-tumor effects in a murine model of breast cancer, Jung et al, (Abstract #A90, poster presentation November 6 from 12:15-3:15 p.m. ET, Session A, Hall C-D)

The Company's immuno-oncology program is pursuing a better understanding of the body's immune response to tumors and is therefore conducting studies with various chemokine receptor inhibitors in combination with checkpoint inhibitors that may result in beneficial anti-tumor effects. Results from a study of one of the Company's inhibitors of the chemokine receptor known as CCR1, CCX9588, demonstrated the ability to act synergistically with a PD-L1 inhibitor to reduce tumor burden in a preclinical model of triple negative breast cancer.

From the abstract, CCX9588, when delivered in combination with an anti-PDL1 antibody, resulted in significantly reduced primary tumor growth and lung metastasis, as compared to either agent alone. In addition, an analysis of tumor-infiltrating cells revealed that the addition of CCX9588 to the anti-PD-L1 antibody significantly reduced the number of myeloid derived suppressor cells (MDSCs) in primary tumors, potentially contributing to the overall reduction of tumor burden. These preclinical results were also accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held from November 4-8, in National Harbor, MD.

"One of the most exciting advances in oncology in decades is the recent observation that modifiers of the activity of the body's own immune system can profoundly enhance the response to chemotherapy," said Israel F. Charo, M.D., Ph.D., Senior Vice President, Research, ChemoCentryx. "We believe that chemokine receptor inhibitors such as CCX9588, combined with immunotherapy or traditional chemotherapy, may result in greater efficacy and fewer systemic side effects."

About the ChemoCentryx Immuno-Oncology Program

CCR1- and CCR2-bearing cells, such as myeloid derived suppressor cells (MDSCs), are thought to possess an immunosuppressive behavior. MDSCs effectively help tumors hide from the body's natural cytotoxic immune response to tumor cells. Inhibiting CCR1 and CCR2, may lead to the liberation of the cytotoxic immune response against tumor cells, reduced tumor burden and potentially lead to improved patient survival.

The Company currently has an ongoing clinical trial of CCX872, an inhibitor of the chemokine receptor known as CCR2, in patients with non-resectable pancreatic cancer. In addition, the Company is conducting preclinical research with various chemokine receptor inhibitors in combination with checkpoint inhibitors, such as those inhibiting the PD-L1 pathway, which may result in a greater anti-tumor effect than with checkpoint inhibition alone. CCX9588 is a small molecule inhibitor of CCR1 and is currently in preclinical development for certain oncology indications targeting both solid and liquid tumors.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX140, a CCR2 inhibitor, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvements in kidney function in patients with diabetic nephropathy. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing both reduction and elimination of high-dose corticosteroids, part of standard of care for AAV patients, without compromising efficacy or safety during a 12-week treatment period. CCX168 is also in Phase II pilot studies for the treatment of atypical Hemolytic Uremic Syndrome (aHUS) and Immunoglobulin A nephropathy, or IgA nephropathy (IgAN). CCX872, a second CCR2 inhibitor, successfully completed Phase I development and is in development for the treatment of non-resectable pancreatic cancer. Vercirnon (also known as Traficet-EN or CCX282) is a specific CCR9 inhibitor for the treatment of inflammatory bowel disease. Other clinical programs include CCX507, a next generation CCR9 inhibitor, which has successfully completed Phase I development and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.

Forward-Looking Statements

ChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding the achievement of anticipated milestones in 2015 and 2016 and whether the Company's drug candidates CCX872 and CCX9588 will be shown to be effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC March 13, 2015 and its other reports which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.chemocentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Source: ChemoCentryx, Inc.

CCXI-G

Contact:
Susan M. Kanaya
Senior Vice President, Finance and
Chief Financial Officer or
Markus J. Cappel, Ph.D.
Chief Business Officer
650.210.2900
investor@chemocentryx.com
Media:
Denise Powell
510.703.9491
denise@redhousecomms.com
Investors:
Kimberly Minarovich
Burns McClellan
212.213.0006
kminarovich@burnsmc.com

GL all....tuna

*XXII* $1.49 +.02 with an ask of $1.50 here....it was April when it reached this level previously and the company has had a number of very bullish accomplishments since then! Their very low nicotine cigarettes where confirmed by The New England Journal of Medicine as being considerably better in a 6 month clinical trial to result in fewer cigarettes smoked and a greater number of people deciding to quit smoking during the double blind trial. Definitely worth your DD imho....GL all...tuna

*XXII* $1.49 +.02 with an ask of $1.50 here....it was April when it reached this level previously and the company has had a number of very bullish accomplishments since then! Their very low nicotine cigarettes where confirmed by The New England Journal of Medicine as being considerably better in a 6 month clinical trial to result in fewer cigarettes smoked and a greater number of people deciding to quit smoking during the double blind trial. Definitely worth your DD imho....GL all...tuna

TRTC .13 up 20% and XXII $1.47 +.07 may test $1.50 very soon!!! Highest close since April and the chart is looking very strong! The CEO said in an October 15, 2015 pr that the cannabis portion of XXII could eventually be worth "hundreds of millions of dollars"....a good read if you missed that PR!! GL everyone!! tuna

TRTC .13 up 20% and XXII $1.47 +.07 may test $1.50 very soon!!! Highest close since April and the chart is looking very strong! The CEO said in an October 15, 2015 pr that the cannabis portion of XXII could eventually be worth "hundreds of millions of dollars"....a good read if you missed that PR!! GL everyone!! tuna

bio NYMX $3.95 new HOD! TRTC .124 MJNA .052 RMHB .09 XXII $1.41 (just turned "green") as the MJ/Hemp sector continues strong again!! GL...tuna

bio NYMX $3.95 new HOD! TRTC .124 MJNA .052 RMHB .09 XXII $1.41 (just turned "green") as the MJ/Hemp sector continues strong again!! GL...tuna

bio NYMX $3.77 at highest level since $3.92 hit on Oct. 29th when big news hit!! Will it take out $3.92 and test $4 soon??? tuna

bio NYMX $3.77 at highest level since $3.92 hit on Oct. 29th when big news hit!! Will it take out $3.92 and test $4 soon??? tuna

MJ SECTOR STILL HOT: MJNA .056 +14% TRTC .113 + 4.5% RMHB .092 +7.4% XXII $1.39 -.01 are only 4 I own in the MJ/HEMP sector...tuna

MJ SECTOR STILL HOT: MJNA .056 +14% TRTC .113 + 4.5% RMHB .092 +7.4% XXII $1.39 -.01 are only 4 I own in the MJ/HEMP sector...tuna

XXII $1.39 overlooked MJ play which is a very hot sector now and the CEO said their cannabis business would eventually be worth HUNDREDS OF MILLIONS in this PR that I have copied partially....Henry Sicignano, III, President and CEO of 22nd Century explained, “In much the same way that we enjoy a monopoly on the nicotinic biosynthetic pathway of tobacco, our license agreement and research activities with Anandia will facilitate 22nd Century’s control of the cannabinoid biosynthetic pathway in cannabis throughout the U.S. market.” Mr. Sicignano continued, “Though not directly related to our main tobacco businesses, the exclusivity in, and control of, ‘next generation cannabis strains’ could ultimately be worth hundreds of millions of dollars to 22nd Century.”

About 22nd Century Group, Inc.

22nd Century Group is a plant biotechnology company focused on technology that allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company’s primary mission is to reduce the harm caused by smoking. 22nd Century currently owns or exclusively controls more than 185 issued patents and more than 50 pending patent applications around the world. The Company’s strong IP position led to a licensing agreement with British American Tobacco (“BAT”), the world’s second largest tobacco company. Visit www.xxiicentury.com for more information.

About Anandia Laboratories Inc.

Anandia Laboratories, Inc. is the emerging leader in cannabis genetics and variety improvement. Building on the pioneering research of Co-Founder Dr. Jonathan Page and utilizing its world-leading intellectual property position, Anandia is applying modern plant breeding approaches and genomics to create next-generation cannabis strains optimized to address grower and consumer challenges. Anandia also continues to contribute to the evolution of the cannabis industry by helping partners through shared knowledge, analytical testing, and genomic analysis services. Visit www.anandialabs.com for more information.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the year ended December 31, 2014, filed on February 6, 2015, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.


View source version on businesswire.com: http://www.businesswire.com/news/home/20151015005774/en/

XXII $1.40 close overlooked MJ play: CEO said in Oct. 15th 2015 pr the cannabis end of their business could ultimately be worth "hundreds of millions of dollars"....here is a part of the pr:

Henry Sicignano, III, President and CEO of 22nd Century explained, “In much the same way that we enjoy a monopoly on the nicotinic biosynthetic pathway of tobacco, our license agreement and research activities with Anandia will facilitate 22nd Century’s control of the cannabinoid biosynthetic pathway in cannabis throughout the U.S. market.” Mr. Sicignano continued, “Though not directly related to our main tobacco businesses, the exclusivity in, and control of, ‘next generation cannabis strains’ could ultimately be worth hundreds of millions of dollars to 22nd Century.”

About 22nd Century Group, Inc.

22nd Century Group is a plant biotechnology company focused on technology that allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company’s primary mission is to reduce the harm caused by smoking. 22nd Century currently owns or exclusively controls more than 185 issued patents and more than 50 pending patent applications around the world. The Company’s strong IP position led to a licensing agreement with British American Tobacco (“BAT”), the world’s second largest tobacco company. Visit www.xxiicentury.com for more information.

About Anandia Laboratories Inc.

Anandia Laboratories, Inc. is the emerging leader in cannabis genetics and variety improvement. Building on the pioneering research of Co-Founder Dr. Jonathan Page and utilizing its world-leading intellectual property position, Anandia is applying modern plant breeding approaches and genomics to create next-generation cannabis strains optimized to address grower and consumer challenges. Anandia also continues to contribute to the evolution of the cannabis industry by helping partners through shared knowledge, analytical testing, and genomic analysis services. Visit www.anandialabs.com for more information.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the year ended December 31, 2014, filed on February 6, 2015, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.


View source version on businesswire.com: http://www.businesswire.com/news/home/20151015005774/en/

GL all....tuna

XXII $1.40 hasn't moved yet like most of the MJ sector even though the CEO in an Oct. 15th 2015 PR said the company's cannabis related business could be worth "hundreds of millions".....here is a small portion of that PR:

....Henry Sicignano, III, President and CEO of 22nd Century explained, “In much the same way that we enjoy a monopoly on the nicotinic biosynthetic pathway of tobacco, our license agreement and research activities with Anandia will facilitate 22nd Century’s control of the cannabinoid biosynthetic pathway in cannabis throughout the U.S. market.” Mr. Sicignano continued, “Though not directly related to our main tobacco businesses, the exclusivity in, and control of, ‘next generation cannabis strains’ could ultimately be worth hundreds of millions of dollars to 22nd Century.”

GL all....tuna

XXII $1.40 hasn't moved yet like most of the MJ sector even though the CEO in an Oct. 15th 2015 PR said the company's cannabis related business could be worth "hundreds of millions".....here is a small portion of that PR:

....Henry Sicignano, III, President and CEO of 22nd Century explained, “In much the same way that we enjoy a monopoly on the nicotinic biosynthetic pathway of tobacco, our license agreement and research activities with Anandia will facilitate 22nd Century’s control of the cannabinoid biosynthetic pathway in cannabis throughout the U.S. market.” Mr. Sicignano continued, “Though not directly related to our main tobacco businesses, the exclusivity in, and control of, ‘next generation cannabis strains’ could ultimately be worth hundreds of millions of dollars to 22nd Century.”

GL all....tuna

Thanks Recon. I'm in XXII and it's been very good to me so far. Like the business they're in regarding biotech created techniques for altering tobacco and marijuana, however, their big success has been on drastically lowering the nicotine in tobacco, which could save millions of lives worldwide if they can gain acceptance. Thanks again...tuna

Can any chartists confirm XXII $1.41 is now in a "golden cross" formation? The stock has been strong since bottoming at .56 about 2 months ago. I copied this definition for golden cross from a website called InvestingAnswers:

"In the trading world, a golden cross occurs when a stock's short-term moving average rises above its long-term moving average....A golden cross is a telltale sign of bullish sentiment for a stock and sometimes for the economy as a whole. Thus, investors who watch technical trading charts tend to buy a stock when the short-term moving average rises above the long-term moving average, and they tend to sell when the short-term moving average falls below the long-term moving average."

Thanks in advance...tuna

Can any chartists confirm XXII $1.41 is now in a "golden cross" formation? The stock has been strong since bottoming at .56 about 2 months ago. I copied this definition for golden cross from a website called InvestingAnswers:

"In the trading world, a golden cross occurs when a stock's short-term moving average rises above its long-term moving average....A golden cross is a telltale sign of bullish sentiment for a stock and sometimes for the economy as a whole. Thus, investors who watch technical trading charts tend to buy a stock when the short-term moving average rises above the long-term moving average, and they tend to sell when the short-term moving average falls below the long-term moving average."

Thanks in advance...tuna

*XXII* $1.44 +.10 close just a penny under the $1.45 recent high of Oct. 20th, just before consolidation kept the stock trading mostly in the high $1.20's to mid $1.30's for several days until today! CETX close $1.69 +.08 on it's acquisition news. RMHB (prev. THCZ) the hemp beverage company closed at .094 up a tad. My new add of NYMX closed at $3.51 but I'm still in it at a small loss now after not selling on 2 different chances in the low $3.70's. It may run again tomorrow based on it's news today. Have a good night all...tuna

*XXII* $1.44 +.10 close just a penny under the $1.45 recent high of Oct. 20th, just before consolidation kept the stock trading mostly in the high $1.20's to mid $1.30's for several days until today! CETX close $1.69 +.08 on it's acquisition news. RMHB (prev. THCZ) the hemp beverage company closed at .094 up a tad. My new add of NYMX closed at $3.51 but I'm still in it at a small loss now after not selling on 2 different chances in the low $3.70's. It may run again tomorrow based on it's news today. Have a good night all...tuna

XXII $1.44 +.10 new HOD! NYMX $3.61 bouncing again w/huge PR in the biotech....CETX $2.70 +.09 on acquisition news today but VLTC backed off from $6.46 HOD and is down to $6.20's now.l....GL all...tuna

XXII $1.42 +.08 new HOD and looking like it's ready to break out of a consolidation phase....broke to $1.45 on Oct. 20th. This tobacco biotech has patents involved with biological rather than chemical means to reduce nicotine in cigarettes and the CEO mentioned recently in a PR he believes they're patents regarding marijuana growing alone are worth "hundreds of millions of dollars"....

Looking like XXII just may be breaking out of it's recent consolidation in the upper $1.20's to mid-$1.30's but all imho.

CETX $2.75 holding up nicely with it's news today of a letter of intent on a new acquisition and mentioned in the PR that the previous acquisition should close "soon".

Still holding NYMX but underwater by about a dime now....liked the news out on it today and staying in VLTC $6.31 until it breaks out for the next of what have been several huge runs in the last few months....GL all...tuna

VLTC $6.46 +.18 HOD...in NYMX $3.58 +.67 big news...CETX $2.77 +.16 w/$3.84 HOD so far....and XXII $1.36 +.02 up from $1.30 LOD...been consolidating gains but maybe about ready to run again and break over $1.40's to test $1.50 next....all imho. GL...tuna

VLTC $6.46 +.18 HOD...in NYMX $3.58 +.67 big news...CETX $2.77 +.16 w/$3.84 HOD so far....and XXII $1.36 +.02 up from $1.30 LOD...been consolidating gains but maybe about ready to run again and break over $1.40's to test $1.50 next....all imho. GL...tuna

*CETX* $2.78 +.18 at HOD and drawing larger bids now...like to see a close around $3 today with good volume! The last 11 consecutive 1 minutes bars are all "green"....and the last 6 are higher volume than any of the previous bars.....GL all...tuna

*CETX* $2.78 +.18 at HOD and drawing larger bids now...like to see a close around $3 today with good volume! The last 11 consecutive 1 minutes bars are all "green"....and the last 6 are higher volume than any of the previous bars. GL all...tuna

*CETX* $2.68 +.07 shot to $5.19 from $2.40 and then from $3.15 to $4.94 with both runs in September!! So this very low floater has some very strong volatility!! GL all....tuna

*CETX* $2.68 +.07 shot to $5.19 from $2.40 and then from $3.15 to $4.94 with both runs in September!! So this very low floater has some very strong volatility!! GL all....tuna

*CETX* $2.61 pe=5 fl=1.66m (per Yahoo stats) news on 2nd acquisition letter of intent signed!! Here is the PR....

Cemtrex (CETX) Enters Into Letter of Intent to Acquire Leading Industrial Filtration Solutions Provider
PR Newswire Cemtrex, Inc.
42 minutes ago


FARMINGDALE, N.Y., Oct. 29, 2015 /PRNewswire/ -- Cemtrex Inc.(CETX), a diversified industrial and manufacturing leader, announced today that it entered into a Letter of Intent on October 28th, 2015, to acquire a leading air filtration solutions provider ("Target") based in the US.

Logo - http://photos.prnewswire.com/prnh/20151029/281763LOGO

The Target is a provider of clean air products and services for industrial, commercial, and municipal facilities in the western United States. The company has been a leader in designing and implementing technology for advanced air quality systems for over 25 years.

Cemtrex's CEO, Saagar Govil, commented, "We are extremely pleased about this acquisition as it will greatly enhance our domestic competitiveness in our industrial filtration business. California typically sets the standard when it comes to environmental practices so acquiring a leader in this market significantly advances our long term strategy in this business. Additionally, we see a lot of room for value addition and cross-selling from our existing filtration and monitoring businesses."

The Target had revenues of approximately $5M and a normalized EBITDA of approximately $.5M in 2014. The purchase price of approximately $1.55M, will be paid with $.4M in cash, $.95M in debt, and $.2M in stock. The company expects the acquisition to close in approximately 90 days. Due to confidentiality reasons further details regarding the Target or the transaction are not available at this time.

Mr. Govil continued, "This is Cemtrex's second announced acquisition in 2015 and fits into the company's strategy of growing both organically as well as through acquisitions. As I always tell prospective investors, Cemtrex is constantly evaluating and negotiating acquisition opportunities, and as the right opportunities present themselves, the Company pursues them aggressively. The company's previously announced acquisition is still pending and is expected to close soon."


8:04 am Cemtrex receives new orders worth over $3 million Briefing.com 1 day 0 hrs ago
Cemtrex, Inc. Earnings Q3, 2015 Capital Cube q 28 days ago
More
For more information on the company's strategy prospective investors can visit the Investor Relations section on the Company's website: www.cemtrex.com

About Cemtrex

Cemtrex, Inc. (CETX) is a world leading diversified industrial and manufacturing company that provides a wide array of solutions to meet today's technology challenges. Cemtrex provides manufacturing services of advanced custom engineered electronics, monitoring instruments for industrial processes and environmental compliance, and systems for controlling particulates, hazardous gases, emissions of Greenhouse gases, and other regulated pollutants used in emissions trading globally.

www.cemtrex.com

Safe Harbor Statement
This press release contains forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date.

For further information, please contact:

Investor Relations
Cemtrex, Inc.
Phone: 631-756-9116
Email

*CETX* $2.61 pe=5 fl=1.66m (per Yahoo stats) news on 2nd acquisition letter of intent signed!! Here is the PR....

Cemtrex (CETX) Enters Into Letter of Intent to Acquire Leading Industrial Filtration Solutions Provider
PR Newswire Cemtrex, Inc.
42 minutes ago


FARMINGDALE, N.Y., Oct. 29, 2015 /PRNewswire/ -- Cemtrex Inc.(CETX), a diversified industrial and manufacturing leader, announced today that it entered into a Letter of Intent on October 28th, 2015, to acquire a leading air filtration solutions provider ("Target") based in the US.

Logo - http://photos.prnewswire.com/prnh/20151029/281763LOGO

The Target is a provider of clean air products and services for industrial, commercial, and municipal facilities in the western United States. The company has been a leader in designing and implementing technology for advanced air quality systems for over 25 years.

Cemtrex's CEO, Saagar Govil, commented, "We are extremely pleased about this acquisition as it will greatly enhance our domestic competitiveness in our industrial filtration business. California typically sets the standard when it comes to environmental practices so acquiring a leader in this market significantly advances our long term strategy in this business. Additionally, we see a lot of room for value addition and cross-selling from our existing filtration and monitoring businesses."

The Target had revenues of approximately $5M and a normalized EBITDA of approximately $.5M in 2014. The purchase price of approximately $1.55M, will be paid with $.4M in cash, $.95M in debt, and $.2M in stock. The company expects the acquisition to close in approximately 90 days. Due to confidentiality reasons further details regarding the Target or the transaction are not available at this time.

Mr. Govil continued, "This is Cemtrex's second announced acquisition in 2015 and fits into the company's strategy of growing both organically as well as through acquisitions. As I always tell prospective investors, Cemtrex is constantly evaluating and negotiating acquisition opportunities, and as the right opportunities present themselves, the Company pursues them aggressively. The company's previously announced acquisition is still pending and is expected to close soon."


8:04 am Cemtrex receives new orders worth over $3 million Briefing.com 1 day 0 hrs ago
Cemtrex, Inc. Earnings Q3, 2015 Capital Cube q 28 days ago
More
For more information on the company's strategy prospective investors can visit the Investor Relations section on the Company's website: www.cemtrex.com

About Cemtrex

Cemtrex, Inc. (CETX) is a world leading diversified industrial and manufacturing company that provides a wide array of solutions to meet today's technology challenges. Cemtrex provides manufacturing services of advanced custom engineered electronics, monitoring instruments for industrial processes and environmental compliance, and systems for controlling particulates, hazardous gases, emissions of Greenhouse gases, and other regulated pollutants used in emissions trading globally.

www.cemtrex.com

Safe Harbor Statement
This press release contains forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date.

For further information, please contact:

Investor Relations
Cemtrex, Inc.
Phone: 631-756-9116
Email

CRWG .047 close! The slot games on FACEBOOK are doing very well....and having tested several personally, I think they're of very high quality in video and sound! The value of the stock on just their casino games alone is a lot more than this imho. I'll hold this long term and added another 20k today on top of the 20k add last week. XXII $1.33 has been consolidating it's gains from .56 just 6-7 weeks ago, but I think it may soon head higher again with nearly no nicotine cigarettes and the strong results of the clinical trials on them, plus waiting for phase III study results also. RMHB had some profit-taking today closing in the low .09's, but the news has been very positive on their record production run this week and increasing sales and distributors continues. VLTC is also looking very jiggly and may be poised for another of it's patented big runs and CETX closed $2.61 with a smallish gain on it's news of $3mil. in new orders, but with it's PE of just 5 and super low float of 1.66mil. shares a check of the 3 month chart will show you how fast it can shoot to $5+.....all imho. GL all...tuna

CRWG .047 close! The slot games on FACEBOOK are doing very well....and having tested several personally, I think they're of very high quality in video and sound! The value of the stock on just their casino games alone is a lot more than this imho. I'll hold this long term and added another 20k today on top of the 20k add last week. XXII $1.33 has been consolidating it's gains from .56 just 6-7 weeks ago, but I think it may soon head higher again with nearly no nicotine cigarettes and the strong results of the clinical trials on them, plus waiting for phase III study results also. RMHB had some profit-taking today closing in the low .09's, but the news has been very positive on their record production run this week and increasing sales and distributors continues. VLTC is also looking very jiggly and may be poised for another of it's patented big runs and CETX closed $2.61 with a smallish gain on it's news of $3mil. in new orders, but with it's PE of just 5 and super low float of 1.66mil. shares a check of the 3 month chart will show you how fast it can shoot to $5+.....all imho. GL all...tuna

VLTC $6.31 + almost 7% on stronger volume than lately. Is this the beginning of the next HUGE RUN??? Doubled up my position recently at $6.01 and waiting as this one moves so fast once it takes off and everyone knows how enormous these frequent runs have been if looking over the 3 + 6 month charts! GL all...tuna

VLTC $6.31 + almost 7% on stronger volume than lately. Is this the beginning of the next HUGE RUN??? Doubled up my position recently at $6.01 and waiting as this one moves so fast once it takes off and everyone knows how enormous these frequent runs have been if looking over the 3 + 6 month charts! GL all...tuna

CETX $2.72 +.17 nearing $2.76 HOD on contract news today!! tuna

CETX $2.72 +.17 nearing $2.76 HOD on contract news today!! tuna

I enjoy the CRWG Casino slot games on FACEBOOK!! Great effects and sound making them really fun!! This stock will take off again....not if but when imho....tuna

CETX at $2.55 only .34 above the 52wk low but reversal begins today imho! Such a low 1.66m float and under 7m shares OS per Yahoo! And this new pr on contract wins looking great! GL...tuna

CETX at $2.55 only .34 above the 52wk low but reversal begins today imho! Such a low 1.66m float and under 7m shares OS per Yahoo! And this new pr on contract wins looking great! GL...tuna